

**Sudan, Republic of**

**Support for Vaccine: Meningococcal type A  
This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b>	Sudan, Republic of																					
<b>2. Vaccine grant number:</b>	16-SDN-08j-Y, 16-SDN-28a-X, 17-SDN-28a-X, 1820-SDN-28a-X																					
<b>3. Date of Decision Letter:</b>	11-Jul-19																					
<b>4. Date of the Partnership Framework Agreement:</b>	December 10, 2013																					
<b>5. Programme title:</b>	New Vaccine Support (NVS), Meningococcal type A, Routine																					
<b>6. Vaccine type:</b>	Meningococcal type A																					
<b>7. Requested product presentation and formulation of vaccine:</b>	Meningococcal type A, 10 dose(s) per vial, LYOPHILISED																					
<b>8. Programme Duration:<sup>1</sup></b>	2016-2020																					
<b>9. Programme Budget (indicative):<sup>2</sup></b>	(subject to the terms of the Partnership Framework Agreement, if applicable)																					
	2016-2018	2019	2020	2021	2022	2023	Total <sup>2</sup>															
Programme Budget (US\$)	2,382,390	909,500	874,500	-	-	-	4,166,390															
<b>10. Vaccine introduction grant</b>	<table border="1" style="width:100%; border-collapse: collapse; margin-bottom: 10px;"> <tr> <th colspan="3">Approval</th> </tr> <tr> <th>Year</th> <th>Grant Number</th> <th>Amount (US\$)</th> </tr> <tr> <td>2016</td> <td>16-SDN-08j-Y</td> <td>1,290,159</td> </tr> </table> <table border="1" style="width:100%; border-collapse: collapse;"> <tr> <th colspan="2">Disbursement</th> </tr> <tr> <th>Disbursement date</th> <th>Amount (US\$)</th> </tr> <tr> <td>11 May, 2016</td> <td>1,290,159</td> </tr> </table>							Approval			Year	Grant Number	Amount (US\$)	2016	16-SDN-08j-Y	1,290,159	Disbursement		Disbursement date	Amount (US\$)	11 May, 2016	1,290,159
Approval																						
Year	Grant Number	Amount (US\$)																				
2016	16-SDN-08j-Y	1,290,159																				
Disbursement																						
Disbursement date	Amount (US\$)																					
11 May, 2016	1,290,159																					
<b>11. Product switch grant</b>	<b>Not applicable</b>																					
<b>12. Indicative Annual Amounts:<sup>3</sup></b>	(subject to the terms of the Partnership Framework Agreement, if applicable)																					
	2016-2018	2019	2020																			
Type of supplies to be purchased with Gavi funds																						
Number of vaccine doses		1,705,000	-																			
Annual Amounts (US\$)	2,382,390	909,500	-																			

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the total amount approved by Gavi.

<b>13. Procurement agency:</b>	UNICEF. The Country shall release its co-financing payments each year to UNICEF.										
<b>14. Self-procurement:</b>	<b>Not applicable.</b>										
<b>15. Co-financing obligations:</b>	According to the co-financing policy, the Country falls within the group: <span style="float: right;">Preparatory transition phase</span>										
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.											
Type of supplies to be purchased with Country funds in each year	<b>2019</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>						
Number of vaccine doses	284,500	323,000	-	-	-						
Number of AD syringes	223,300	249,200	-	-	-						
Number of re-constitution syringes	31,300	35,600	-	-	-						
Number of safety boxes	2,825	3,150	-	-	-						
Value of vaccine doses (US\$)	147,799	167,915	-	-	-						
Total co-financing payments (US\$) (including freight)	163,500	185,500	-	-	-						
<b>16. Operational support for catch-up campaigns:</b>	<b>Not applicable</b>										
<b>17. Additional Reporting Requirements:</b>	<table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> <li>Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul> </td> <td>           March 31, 2020            May 15, 2020 </td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>Periodicity and dates to be agreed with Gavi Secretariat</td> </tr> </tbody> </table>						Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> <li>Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	March 31, 2020 May 15, 2020	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	Periodicity and dates to be agreed with Gavi Secretariat
	Due dates										
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> <li>Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	March 31, 2020 May 15, 2020										
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	Periodicity and dates to be agreed with Gavi Secretariat										

<b>18. Financial clarifications:</b>	Country shall provide the following clarifications to Gavi*:
<b>Not applicable.</b>	
* Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.	
<b>19. Other conditions:</b>	
<b>Not applicable.</b>	

On behalf of Gavi



Pascal Bijleveld  
Managing Director, Country Programmes a.i.